| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nurix Therapeutics, Inc. (NRIX) has 5 insiders with recent SEC Form 4 filings, including 0 buys and 21 sells. NRIX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 50.0K | $927.5K | - | |
| CFO | 47.4K | $879.8K | - | |
| Dir | 22.6K | $418.9K | - | |
| Other | 15.0K | $278.3K | - | |
| Other | 13.6K | $251.9K | -8,148 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 8, 2021 | Beaurang Pierre64 | Chief Business Officer | Sale+OE | 7,500 | $37.02 | $277,678.49 | -60.5% | |
| Mar 1, 2021 | Hansen Gwenn73 | Chief Scientific Officer | Sale+OE | 800 | $35.95 | $28,760.00 | -5.5% | |
| Feb 24, 2021 | Van Houte Hans60 | Chief Financial Officer | Sale+OE | 35,419 | $39.90 | $1,413,218.10 | -100% | |
| Feb 22, 2021 | Van Houte Hans60 | Chief Financial Officer | Sale+OE | 5,330 | $39.93 | $212,839.16 | -100% | |
| Feb 18, 2021 | Van Houte Hans60 | Chief Financial Officer | Sale+OE | 13,583 | $35.46 | $481,621.05 | -42.1% | |
| Feb 18, 2021 | Ring Christine77 | General Counsel | Sale+OE | 2,000 | $35.88 | $71,750.35 | -48.8% | |
| Feb 18, 2021 | Beaurang Pierre64 | Chief Business Officer | Sale+OE | 15,000 | $35.49 | $532,351.76 | -40.6% | |
| Feb 18, 2021 | Hansen Gwenn73 | Chief Scientific Officer | Sale+OE | 800 | $36.27 | $29,018.02 | -3.2% |